Askbio Inc.
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Asklepios Biopharmaceutical, Inc. (to 2025)
4
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 20, 2027The maintenance fee for Modified Soluble VEGF RECEPTOR-1 Genes and Vectors for Gene Therapy (US 10,385,112) comes due Feb 20, 2027. Unpaid by Aug 20, 2027, it lapses early.
- 1 fee due Jun 17, 2027The maintenance fee for Method for the Construction of Specific Promoters (US 10,508,275) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 23, 2026
- Oct 27 US D1,155,799 Fiducial Delivery Device
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,632,765 | Modified factor VIII and factor IX genes and vectors for gene therapy In force · USPTO record | In force | USPTO record | |
| US 9,506,052 | Modified factor VIII and factor IX genes In force (reinstated) · USPTO record | In force (reinstated) | USPTO record | |
| US 8,198,421 | Modified factor VIII and factor IX genes and vectors for gene therapy In force · USPTO record | In force | USPTO record | |
| US 10,065,021 | Convection-enhanced delivery catheter with removable stiffening member and method for using same In force · USPTO record | In force | USPTO record | |
| US 10,385,112 | Modified Soluble VEGF RECEPTOR-1 Genes and Vectors for Gene Therapy In force · High confidence | In force | High confidence | |
| US 11,414,678 | Modified Soluble VEGF RECEPTOR-1 Genes and Vectors for Gene Therapy In force · High confidence | In force | High confidence | |
| US 10,508,275 | Method for the Construction of Specific Promoters In force · High confidence | In force | High confidence | |
| US 11,492,618 | Expression Control Using a Regulatable Intron In force · High confidence | In force | High confidence | |
| US 12,600,969 | Expression Control Using a Regulatable Intron In force · High confidence | In force | High confidence | |
| US 11,235,070 | Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexes In force (reinstated) · Medium confidence | In force (reinstated) | Medium confidence |
Also on record, not counted in the 21: 1 patent in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 no status recorded
Showing 1 to 2 of 2, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. No title is shown: the bulk publication record carries none for these applications, and this site holds no USPTO file history for them.
| Application | Filed | Status |
|---|---|---|
| 18/864,134 | Jun 22, 2023 | No status recorded |
| 18/857,723 | Apr 20, 2023 | No status recorded |